Adult T-cell leukemia: Future prophylaxis and immunotherapy

Expert Review of Anticancer Therapy

Volumn 4, Issue 3, 2004, Pages 369-376

  Kannagi, Mari ^a   Harashima, Nanae ^a   Kurihara, Kiyoshi ^a   Utsunomiya, Atae ^b   Tanosaki, Ryuji ^c   Masuda, Masato ^d  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b IMAMURA BUN IN HOSPITAL   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

^d UNIVERSITY OF THE RYUKYUS   (Japan)

Author keywords

Adult T cell leukemia; Hematopoietic stem cell transplantation; Human T cell leukemia virus Type I; T cell response; Tax

Indexed keywords

B7 ANTIGEN; CANCER VACCINE; CD86 ANTIGEN; DNA VACCINE; HLA ANTIGEN; MONOCLONAL ANTIBODY; TAX PROTEIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; CANCER IMMUNOTHERAPY; CANCER PATIENT; DISEASE MODEL; DRUG EFFICACY; DRUG TARGETING; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN T CELL LEUKEMIA VIRUS; IMMUNE RESPONSE; IN VIVO STUDY; INCUBATION TIME; LYMPHOCYTE TRANSFER; NONHUMAN; PROPHYLAXIS; RAT; REVIEW; RISK FACTOR; RISK REDUCTION; T CELL LEUKEMIA; T LYMPHOCYTE; TREATMENT INDICATION; TUMOR IMMUNITY; VIRUS CARRIER; VIRUS LOAD;

EID: 2942542883     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.4.3.369     Document Type: Review

References (63)

1. Hinuma Y, Nagata K, Hanaoka M et al. Adult T-cell leukemia: antigen in an ATL cell line and detection of antibodies to the antigen in human sera. Proc. Natl Acad. Sci. USA 78, 6476-6480 (1981).
2. Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc. Natl Acad. Sci. USA 77, 7415-7419 (1980).
3. Yoshida M. Multiple viral strategies of HTLV-1 for dysregulation of cell growth control. Ann. Rev. Immunol. 19, 475-496 (2001).
4. Maloney EM, Blattner WA. HTLV-I worldwide patterns and disease associations. In: Gann Monograph on Cancer Research, volume 50. Sugamura K, Uchiyama T, Matsuoka M, Kannagi M (Eds), Science Societies Press, Japan, 339-361 (2003).
5. Arisawa K, Soda M, Endo S et al. Evaluation of adult T-cell leukemia/lymphoma incidence and its impact on non-Hodgkin lymphoma incidence in southwestern Japan. Int. J. Cancer 85, 319-324 (2000).
6. Tajima K. The fourth nation-wide study of adult T-cell leukemia/lymphoma (ATL) in Japan: estimates of risk of ATL and its geographical and clinical features. The T- and B-cell. Malignancy Study Group. Int. J. Cancer 45, 237-243 (1990).
7. Gessain A, Barin F, Vernant JC et al. Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet 2, 407-410 (1985).
8. Osame M, Usuku. K, Izumo S et al. HTLV-I associated myelopathy, a new clinical entity. Lancet 1, 1031-1032 (1986).
9. Yoshida M, Seiki M, Yamaguchi K, Takatsuki K. Monoclonal integration of human T-cell leukemia provirus in all primary tumors of adult T-cell leukemia suggests causative role of human T-cell leukemia virus in the disease. Proc. Natl Acad. Sci. USA 81, 2534-2537 (1984).
10. Furukawa Y, Fujisawa J, Osame M et al. Frequent clonal proliferation of human T-cell leukemia virus Type 1 (HTLV-1)-infected T-cells in HTLV-1-associated myelopathy (HAM-TSP). Blood 80, 1012-1016 (1992).
11. Tsukahara T, Kannagi M, Ohashi T et al. Induction of Bcl-x(L) expression by human T-cell leukemia virus Type 1 Tax through NF-κB in apoptosis-resistant T-cell transfectants with Tax. J. Virol. 73, 7981-7987 (1999).
12. Iwai K, Mori N, Oie M, Yamamoto N, Fujii M. Human T-cell leukemia virus Type 1 tax protein activates transcription through AP-1 site by inducing DNA binding activity in T-cells. Virology 279, 38-46 (2001).
13. Mulloy JC, Kislyakova T, Cereseto A et al. Human T-cell lymphotropic/leukemia virus Type 1 Tax abrogates p53-induced cell cycle arrest and apoptosis through its CREB/ATF functional domain. J. Virol. 72, 8852-8860 (1998).
14. Hinuma Y, Gotoh Y, Sugamura K et al. A retrovirus associated with human adult T-cell leukemia: in vitro activation. Gann 73, 341-344 (1982).
15. Kinoshita T, Shimoyama M, Tobinai K et al. Detection of mRNA fbr the tax1/rex1 gene of human T-cell leukemia virus Type I in fresh peripheral blood mononuclear cells of adult T-cell leukemia patients and viral carriers by using the polymerase chain reaction. Proc. Natl Acad. Sci. USA 86, 5620-5624(1989).
16. Uchiyama T. Human T-cell leukemia virus Type I (HTLV-I) and human diseases. Ana. Rev. Immunol. 15, 15-37 (1997).
17. Hanon E, Stinchcombe JC, Saito M et al. Fratricide among CD8(+) T-lymphocytes naturally infected with human T-cell lymphotropic virus Type I. Immunity 13, 657-464 (2000).
18. Kannagi M, Matsushita S, Shida H, Harada S. Cytotoxic T-cell response and expression of the target antigen in HTLV-I infection. Leukemia 8(Suppl. 1), S54-S59 (1994).
19. Mori N, Fujii M, Ikeda S et al. Constitutive activation of NF-κB in primary adult T-cell leukemia cells. Blood 93, 2360-2368 (1999).
20. Uchiyama T, Yodoi J, Sagawa K, Takatsuki K, Uchino H. Adult T-cell leukemia: clinical and hematologic features of 16 cases. Blood 50, 481-492 (1977).
21. Shimoyama M, Ota K, Kikuchi M et al. Major prognostic factors of adult patients with advanced T-cell lymphoma/leukemia. J. Clin. Oncol. 6, 1088-1097 (1988).
22. Waldmann TA, White JD, Goldman CK et al. The interleukin-2 receptor: a target for monoclonal antibody treatment of human T-cell lymphotrophic virus I-induced adult T-cell leukemia. Blood 82, 1701-1712 (1993).
23. Gill PS, Harrington W Jr, Kaplan MH et al. Treatment of adult T-cell leukemia-lymphoma with a combination of interferon-α and zidovudine. N. Engl. J. Med. 332, 1744-1748 (1995).
24. Hermine O, Bouscary D, Gessain A et al. Brief report: treatment of adult T-cell leukemia-lymphoma with zidovudine and interferon-α. N. Engl. J. Med. 332, 1749-1751 (1995).
25. Nasr R, Rosenwald A, El-Sabban ME et al. Arsenic/interferon specifically reverses two distinct gene networks critical for the survival of HTLV-1-infected leukemic cells. Blood 101, 4576-4582 (2003).
26. Tsukasaki K, Maeda T, Arimura K et al. Poor outcome of autologous stem cell transplantation for adult T-cell leukemia/lymphoma: a case report and review of the literature. Bone Marrow Transplant. 23, 87-89 (1999).
27. Utsunomiya A, Miyazaki Y, Takatsuka Y et al. Improved outcome of adult T-cell leukemia/lymphoma with allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 27, 15-20 (2001).
28. Daenke S, Nightingale S, Cruickshank JK, Bangham CR. Sequence variants of human T-cell lymphotropic virus Type I from patients with tropical spastic paraparesis and adult T-cell leukemia do not distinguish neurological from leukemic isolates. J. Virol. 64, 1278-1282 (1990).
29. Kinoshita T, Tsujimoto A, Shimotohno K. Sequence variations in LTR and env regions of HTLV-I do not discriminate between the virus from patients with HTLV-I-associated myelopathy and adult T-cell leukemia. Int. J. Cancer 47, 491-495 (1991).
30. Kannagi M, Sugamura K, Sato H, Okochi K, Uchino H, Hinuma Y. Establishment of human cytotoxic T-cell lines specific for human adult T-cell leukemia virus-bearing cells. J. Immunol. 130, 2942-2946 (1983).
31. Kannagi M, Sugamura K, Kinoshita K, Uchino H, Hinuma Y. Specific cytolysis of fresh tumor cells by an autologous killer T-cell line derived from an adult T-cell leukemia/lymphoma patient. J. Immunol. 133, 1037-1041 (1984).
32. + cytotoxic T-lymphocytes specific for HTLV-I pX in patients with HTLV-I associated neurological disease. Nature 348, 245-248 (1990).
33. Parker CE, Daenke S, Nightingale S, Bangham CR. Activated, HTLV-1-specific cytotoxic T-lymphocytes are found in healthy seropositives as well as in patients with tropical spastic paraparesis. Virology 188, 628-636 (1992).
34. + cytotoxic T-cells directed against HTLV-I-infected cells. Int. Immunol. 3, 761-767 (1991).
35. Goon PK, Hatton E, Igakura T et al. High frequencies of Th1-type CD4(+) T-cells specific to HTLV-1 Env and Tax proteins in patients with HTLV-1-associated myelopathy/tropical spastic paraparesis. Blood 99, 3335-3341 (2002).
36. Overbaugh J, Bangham CR. Selection forces and constraints on retroviral sequence variation. Science 292, 1106-1109 (2001).
37. Furukawa Y, Kubota R, Tara M, Izumo S, Osame M. Existence of escape mutant in HTLV-I tax during the development of adult T-cell leukemia. Blood 97, 987-993 (2001).
38. + T-cell response to Tax in human T-cell leukemia virus Type 1-infected patients with adult T-cell leukemia/lymphoma. Leukemia 18, 126-132 (2004).
39. Kannagi M, Matsushita S, Harada S. Expression of the target antigen for cytotoxic T-lymphocytes on adult T-cell-leukemia cells. Int. J. Cancer 54, 582-588 (1993).
40. Ohashi T, Hanabuchi S, Kato H et al. Induction of adult T-cell leukemia-like lymphoproliferative disease and its inhibition by adoptive immunotherapy in T-cell-deficient nude rats inoculated with syngeneic human T-cell leukemia virus Type 1-immortalized cells. J. Virol. 73, 6031-6040 (1999).
41. Hanabuchi S, Ohashi T, Koya Y et al. Development of human T-cell leukemia virus Type 1-transformed tumors in rats following suppression of T-cell immunity by CD80 and CD86 blockade. J. Virol. 74, 428-435 (2000).
42. Hanabuchi S, Ohashi T, Koya Y et al. Regression of human T-cell leukemia virus Type I (HTLV-I)-associated lymphomas in a rat model: peptide-induced T-cell immunity. J. Natl Cancer Inst. 93, 1775-1783 (2001).
43. Ohashi T, Hanabuchi S, Kato H et al. Prevention of adult T-cell leukemia-like lymphoproliferative disease in rats by adoptively transferred T-cells from a donor immunized with human T-cell leukemia virus Type 1 Tax-coding DNA vaccine. J. Virol. 74, 9610-9616 (2000).
44. Hisada M, Okayama A, Tachibana N et al. Predictors of level of circulating abnormal lymphocytes among human T-lymphotropic virus Type I carriers in Japan. Int. J. Cancer 77, 188-192 (1998).
45. Hisada M, Okayama A, Spiegelman D, Mueller NE, Stuver SO. Sex-specific mortality from adult T-cell leukemia among carriers of human T-lymphotropic virus Type I. Int. J. Cancer 91, 497-499 (2001).
46. Tajima K, Hinuma Y. Epidemiology of HTLV-I/II in Japan and the world. In: Gann Monograph on Cancer Research, volume 39. Yoshida M (Ed.), Japan Science Societies Press, 129 (1992).
47. Usuku K, Sonoda S, Osame M et al. HLA haplotype-linked high immune responsiveness against HTLV-I in HTLV-I-associated myelopathy: comparison with adult T-cell leukemia/lymphoma. Ann. Neurol. 23(Suppl.), S143-S150 (1988).
48. Kato H, Koya Y, Ohashi T et al. Oral administration of human T-cell leukemia virus Type 1 induces immune unresponsiveness with persistent infection in adult rats. J. Virol. 72, 7289-7293 (1998).
49. Hasegawa A, Ohashi T, Hanabuchi S et al. Expansion of human T-cell leukemia virus type 1 (HTLV-1) reservoir in orally infected rats: inverse correlation with HTLV-1-specific cellular immune response. J. Virol. 77, 2956-2963 (2003).
50. Hino S. Primary prevention of adult T-cell leukemia (ATL) in Nagasaki, Japan by refraining from breast-feeding. In: Gann Monograph on Cancer Research, volume 50. Sugamura K, Uchiyama T. Matsuoka M, Kannagi M (Eds), Japan Science Societies Press, 241-251 (2003).
51. Kinoshita K, Yamanouchi K, Ikeda S et al. Oral infection of a common marmoset with human T-cell leukemia virus type-I (HTLV-I) by inoculating fresh human milk of HTLV-I carrier mothers. Jpn. J. Cancer Pes. 76, 1147-1153 (1985).
52. Nakano S, Ando Y, Saito K et al. Primary infection of Japanese infants with adult T-cell leukemia-associated retrovirus (ATLV): evidence for viral transmission from mothers to children. J. Infect. 12, 205-212 (1986).
53. Kusuhara K, Sonoda S, Takahashi K, Tokugawa K, Fukushige J, Ueda K. Mother-to-child transmission of human T-cell leukemia virus Type I (HTLV-I): a fifteen-year follow-up study in Okinawa, Japan. Int. J. Cancer 40, 755-757 (1987).
54. MacDonald TT. T-cell immunity to oral allergens. Curr. Opin. Immunol. 10, 620-627 (1998).
55. Wodarz D, Hall SE, Usuku K et al. Cytotoxic T-cell abundance and virus load in human immunodeficiency virus Type 1 and human T-cell leukemia virus Type 1. Proc. R. Soc. Lond. B. Biol. Sci. 268, 1215-1221 (2001).
56. + T-cells in cerebrospinal fluid from patients with HAM/TSP. Ann. Neurol. 50, 807-812 (2001).
57. Harashima N, Kurihara K, Utsunomiya A et al. Graft-versus-Tax response in adult T-cell leukemia patients after hematopoietic stem cell transplantation. Cancer Res. 64, 391-399 (2004).
58. Goulmy E, Schipper R, Pool J et al. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft versus host disease after bone marrow transplantation. N. Engl. J. Med. 334, 281-285 (1996).
59. Kannagi M, Shida H, Igarashi H et al. Target epitope in the Tax protein of human T-cell leukemia virus Type I recognized by class I major histocompatibility complex-restricted cytotoxic T-cells. J. Virol. 66, 2928-2933 (1992).
60. Jeffery KJ, Usuku K, Hall SE et al. HLA alleles determine human T-lymphotropic virus-I (HTLV-I) proviral. load and the risk of HTLV-I-associated myelopathy. Proc. Natl Acad. Sci. USA 96, 3848-3853 (1999).
61. Lehky TJ, Fox CH, Koenig S et al. Detection of human T-lymphotropic virus Type I (HTLV-I) tax RNA in the central nervous system of HTLV-I-associated myelopathy/tropical spastic paraparesis patients by in situ hybridization. Ann. Neurol. 37, 167-175 (1995).
62. Levin MC, Lehky TJ, Flerlage AN et al. Immunologic analysis of a spinal cord-biopsy specimen from a patient with human T-cell lymphotropic virus Type I-associated neurologic disease. N. Engl. J. Med. 336, 839-845 (1997).
63. Bangham CR. The immune response to HTLV-I. Curr. Opin. Immunol. 12, 397-402 (2000).